Adjuvant pertuzumab in HER2 breast cancer: APHINITY

A 52-year-old nurse had a 2.5 cm nodule in the right breast operated on without treatment before surgery, because the tumor looked small and the axilla looked normal on examination. The pathology report on the specimen brought a surprise: HER2-positive invasive carcinoma, with positive estrogen receptor, and 3 of 14 axillary lymph nodes with metastasis. The echocardiogram shows an ejection fraction of 58 percent. She has controlled high blood pressure and is overweight. The oncologist plans chemotherapy with anthracycline and taxane and wants to decide whether to add pertuzumab to trastuzumab. The scene is fictional and was written for teaching.

This text uses the case as a clinical reasoning scenario for students and health professionals. The topic is adjuvant pertuzumab in HER2-positive breast cancer, tested in the APHINITY trial. The focus is weighing the absolute benefit, which depends heavily on baseline risk and especially on the lymph nodes, against toxicity and cost. It does not replace your institution's protocol or the multidisciplinary team's decision. If you play the case of the day on NEXO, you will recognize the challenge: the same hazard ratio can mean a lot for one person and little for another.

Key points

• APHINITY randomized 4805 patients who had undergone surgery to receive trastuzumab with pertuzumab or with placebo, along with adjuvant chemotherapy, for 1 year.
• In the primary analysis, the hazard ratio for invasive disease or death was 0.81, but the absolute difference at 3 years was small, 94.1 versus 93.2 percent.
• The benefit appeared mainly with positive lymph nodes; without positive lymph nodes, no effect was detected.
• In the final overall survival analysis in the label, the hazard ratio was 0.83, with an interval of 0.69 to 1.00.
• Diarrhea was the adverse effect that increased the most, and serious cardiac events were rare.
• The FDA approved adjuvant use on 12/20/2017, and the EMA committee gave a favorable opinion on 04/26/2018.

Why this is a reasoning scenario

Trastuzumab with chemotherapy changed the prognosis of early HER2-positive breast cancer, and 1 year of trastuzumab became the standard (von Minckwitz et al., 2017). Pertuzumab binds to another region of the HER2 receptor and prevents it from pairing with other receptors of the same family (von Minckwitz et al., 2017). In metastatic disease and in treatment before surgery, adding the two antibodies had already shown a gain (von Minckwitz et al., 2017). APHINITY asked whether adding them also helped after surgery (von Minckwitz et al., 2017).

The answer was yes, but with a small absolute gain for most and a larger one for those at higher risk (von Minckwitz et al., 2017). That is why adjuvant pertuzumab is a good reasoning exercise: the decision depends not only on the trial having been positive, but on how much that patient gains. The post on signs, symptoms and history helps you not forget the nurse's high blood pressure and overweight, which weigh on heart risk, and the post on clinical decision-making reminds you that the lymph node report is the central clue.

What the scene teaches

The scene trains six habits. The first is to look at the lymph nodes before looking at tumor size. The second is to translate the hazard ratio into absolute benefit for that patient. The third is to check the heart before and during treatment. The fourth is to warn about diarrhea. The fifth is to know in what order the anthracycline, the taxane and the antibodies come in. The sixth is to explain that the goal is to reduce the risk of recurrence, not to guarantee a cure.

What is not at stake

The text does not repeat the discussion about T-DM1 in residual disease after neoadjuvant treatment, which was the topic of the previous text in this series, on T-DM1 in residual disease. It also does not cover extended neratinib after 1 year of trastuzumab, tested in another trial (Copeland and Anders, 2018). The post on diagnostic uncertainty helps when the lymph node report leaves doubt.

Who is a candidate: the weight of the lymph nodes

Positive lymph node

In APHINITY, 63 percent had positive lymph nodes (von Minckwitz et al., 2017). In this group, 92.0 percent of the pertuzumab arm and 90.2 percent of the placebo arm were alive and free of invasive disease at 3 years, with a hazard ratio of 0.77 and an interval of 0.62 to 0.96 (von Minckwitz et al., 2017). At 6 years, the numbers were 87.9 versus 83.4 percent, with a hazard ratio of 0.72 (Krawczyk et al., 2022). The nurse in the scene, with 3 positive lymph nodes, is in this group.

Negative lymph node

Among those who did not have positive lymph nodes, there were few events, 3.6 percent with pertuzumab and 3.2 percent with placebo, and no treatment effect was detected (von Minckwitz et al., 2017). At 6 years, the numbers remained similar, 95 versus 94.9 percent (Krawczyk et al., 2022). In the EMA report, the hazard ratio in this group was 1.13, with an interval of 0.68 to 1.86, with no evidence of benefit at that time (EMA assessment report, 2018). A later analysis of the same study also concluded that the benefit was limited to those with positive lymph nodes (Maurer et al., 2025).

Hormone receptor negative

Among those who were hormone receptor negative, the hazard ratio was 0.76, with an interval of 0.56 to 1.04 (von Minckwitz et al., 2017). The interval includes the value 1. Even so, the EMA restricted the indication to patients at high risk of recurrence, defined as positive lymph nodes or hormone receptor negative (EMA assessment report, 2018). The post on differential diagnosis helps separate what is high risk from what only looks high.

Absolute benefit

Based on the risk avoided at 3 years, 112 patients needed to be treated to prevent one event in the overall population, 56 with positive lymph nodes and 63 with hormone receptor negative (von Minckwitz et al., 2017). The authors note that the hazard ratio of 0.81 must be weighed against the absolute risk of recurrence (von Minckwitz et al., 2017). An Italian review sums up the same idea: the gain is small in the general population and larger in high-risk patients with positive lymph nodes (Stucci et al., 2022). The post on interprofessional clinical reasoning shows why the conversation about cost and benefit involves more than one person on the team.

What APHINITY tested

Design

APHINITY was a phase 3, randomized, multicenter, double-blind, placebo-controlled study, conducted at 549 centers in 43 countries (von Minckwitz et al., 2017). Between November 2011 and August 2013, 4805 patients were randomized, 2400 to pertuzumab and 2405 to placebo (von Minckwitz et al., 2017). All had HER2-positive invasive cancer without metastasis, operated on with adequate margins (von Minckwitz et al., 2017). The ejection fraction had to be at least 55 percent (von Minckwitz et al., 2017).

A change along the way

At first, patients without positive lymph nodes were also enrolled if they had a tumor larger than 1 cm or between 0.5 and 1 cm with risk factors (von Minckwitz et al., 2017). After 3655 randomizations, an amendment began accepting only patients with positive lymph nodes, to reach the planned distribution (von Minckwitz et al., 2017). According to the EMA, the proportion of patients without positive lymph nodes was nearly double what was expected, and for this reason recruitment of this group was limited and the planned size rose to 4800 (EMA assessment report, 2018).

The two arms

Pertuzumab or placebo was given at a loading dose of 840 mg intravenously, followed by 420 mg every 3 weeks (von Minckwitz et al., 2017). Trastuzumab was given at a loading dose of 8 mg/kg, followed by 6 mg/kg every 3 weeks (von Minckwitz et al., 2017). Both started in the first taxane cycle and continued for up to 18 cycles over 1 year (von Minckwitz et al., 2017). Chemotherapy could be anthracycline followed by taxane or docetaxel with carboplatin (von Minckwitz et al., 2017).

Hormone therapy and radiotherapy

Those who were hormone receptor positive started hormone therapy at the end of chemotherapy, planned for at least 5 years (von Minckwitz et al., 2017). Radiotherapy was given at the end of chemotherapy, at the same time as the antibodies (von Minckwitz et al., 2017). Ejection fraction was measured every 3 months during treatment (von Minckwitz et al., 2017).

What APHINITY showed

Primary analysis

With a median follow-up of 45.4 months, an invasive disease event occurred in 7.1 percent of the pertuzumab arm and in 8.7 percent of the placebo arm (von Minckwitz et al., 2017). At 3 years, 94.1 percent and 93.2 percent were alive and free of invasive disease, with a hazard ratio of 0.81 and an interval of 0.66 to 1.00 (von Minckwitz et al., 2017). The placebo group did better than planned, 93.2 instead of 89.2 percent, and so the study took longer to gather the events (von Minckwitz et al., 2017). Distant metastasis was the first event in 4.7 percent versus 5.8 percent (von Minckwitz et al., 2017).

Overall survival

In the first interim analysis, 80 patients in the pertuzumab arm and 89 in the placebo arm died, with no significant difference (von Minckwitz et al., 2017). At 6 years, the hazard ratio for death was 0.85, still without significance (Krawczyk et al., 2022). In the final analysis planned after 10 years of follow-up, described in the prescribing information, 8.5 percent of the pertuzumab arm and 10.3 percent of the placebo arm died, with a hazard ratio of 0.83 and an interval of 0.69 to 1.00 (Perjeta prescribing information of 04/2026). Among those who were node positive, a long-term follow-up analysis cited in 2026 gives a hazard ratio of 0.79 for overall survival, with an interval of 0.64 to 0.97 (Mattar et al., 2026). Another 2026 text describes this improvement as significant but modest in absolute terms (Valachis et al., 2026).

The table summarizes the main numbers.

Measure	Pertuzumab	Placebo	Source
Free of invasive disease at 3 years, all	94.1 percent	93.2 percent	(von Minckwitz et al., 2017)
Free of invasive disease at 3 years, node positive	92.0 percent	90.2 percent	(von Minckwitz et al., 2017)
Free of invasive disease at 6 years, node positive	87.9 percent	83.4 percent	(Krawczyk et al., 2022)
Number needed to treat at 3 years, node positive	56	Reference	(von Minckwitz et al., 2017)
Hazard ratio for death, final analysis	0.83 (0.69 to 1.00)	Reference	(Perjeta prescribing information of 04/2026)

Age

Of the patients in the study, 768, 16.0 percent, were 40 years old or younger (Lambertini et al., 2022). Pertuzumab improved invasive disease-free survival at 6 years both in younger women, 89 versus 87 percent, and in older women, 91 versus 88 percent (Lambertini et al., 2022). Young age did not change the result significantly (Lambertini et al., 2022).

Fixed dose

The pertuzumab dose does not depend on weight. A pharmacokinetic analysis of APHINITY supports the fixed dose of 840 mg followed by 420 mg every 3 weeks, as had already been seen in neoadjuvant treatment (Kirschbrown et al., 2019). The post about diagnostic pause helps to check the prescription before the first infusion.

In real life

In a national study from Sweden, survival of node-positive patients was lower than that of the APHINITY control arm, which had 89.2 percent survival at 8.4 years (Valachis et al., 2026). The authors suggest that, if the same relative reduction holds, the absolute benefit outside the study may be greater (Valachis et al., 2026). In Brazil, a model estimated that bringing adjuvant T-DM1 and pertuzumab to women with stage II and III HER2-positive cancer in the public system would substantially reduce avoidable deaths at 8 years (Mattar et al., 2026). A network meta-analysis suggested that adding lapatinib or pertuzumab to trastuzumab is probably the best strategy for survival (Debiasi et al., 2018).

How to use adjuvant pertuzumab

Dose and infusion

The label indicates 840 mg for the first dose, as a 60-minute infusion, and then 420 mg every 3 weeks, as a 30- to 60-minute infusion (Perjeta label of 04/2026). In adjuvant use, pertuzumab is given with trastuzumab and chemotherapy for 1 year, up to 18 cycles, starting on the first day of the first cycle with a taxane (Perjeta label of 04/2026). Anyone receiving an anthracycline should receive pertuzumab and trastuzumab after finishing the anthracycline (Perjeta label of 04/2026). The label recommends observing the patient for 30 to 60 minutes after each pertuzumab infusion, before the next medication (Perjeta label of 04/2026).

Dose delay

If the interval between two doses is less than 6 weeks, 420 mg is given as soon as possible (Perjeta label of 04/2026). If it is 6 weeks or more, the 840 mg loading dose is repeated and then 420 mg every 3 weeks resumes (Perjeta label of 04/2026). The only contraindication in the label is known hypersensitivity to pertuzumab or to the components of the formulation (Perjeta label of 04/2026).

The heart

In the primary analysis, serious cardiac events occurred in 0.7 percent of the pertuzumab arm and 0.3 percent of the placebo arm (von Minckwitz and colleagues, 2017). In the cardiac analysis with a median of 74 months, the combination of the two antibodies did not increase the risk of a cardiac event compared with placebo (de Azambuja and colleagues, 2023). Besides the anthracycline, age 65 or older, body mass index of 25 or more and an initial ejection fraction of 55 to less than 60 percent were risk factors (de Azambuja and colleagues, 2023). The label reports symptomatic heart failure in 0.6 percent of those treated with adjuvant pertuzumab, and 86 percent of these events were in those who received an anthracycline (Perjeta label of 04/2026). The boxed warning in the label mentions left ventricular dysfunction and harm to the fetus (Perjeta label of 04/2026).

Diarrhea and other effects

Grade 3 or higher diarrhea was the biggest difference between the arms, 9.8 percent versus 3.7 percent (von Minckwitz and colleagues, 2017). After chemotherapy ended, with the antibodies alone, grade 3 or higher diarrhea fell to 0.5 percent (von Minckwitz and colleagues, 2017). Adding all grades, diarrhea was 71.2 percent versus 45.2 percent, and rash was 25.8 percent versus 20.3 percent (von Minckwitz and colleagues, 2017). The full 1 year was completed by 84.5 percent of the pertuzumab arm (von Minckwitz and colleagues, 2017). A review recalls that diarrhea, the heart and cost all count (Bulbul and colleagues, 2018).

Monitoring can follow the points below.

• Ejection fraction before starting and every 3 months during treatment.
• Greater attention with an anthracycline, age 65 or older, excess weight and a borderline initial ejection fraction.
• Guidance on diarrhea, hydration and when to seek care.
• Observation for 30 to 60 minutes after each pertuzumab infusion.
• Effective contraception during treatment, because of the risk to the fetus.

The post on clinical deterioration on the ward helps recognize the worsening of a patient dehydrated by diarrhea.

Pertuzumab or T-DM1?

When treatment starts before surgery, the choice after the operation depends on the response. Those with a pathologic complete response complete 1 year of pertuzumab with trastuzumab, as the label provides (Perjeta label of 04/2026). Those with residual invasive disease enter the T-DM1 scenario, discussed in the text on T-DM1 in residual disease. A 2019 review summarizes the place of pertuzumab in the different scenarios (Ishii and colleagues, 2019).

Regulatory status: FDA and EMA

FDA

Perjeta has BLA 125409 at the FDA, with original approval on 06/08/2012 (Drugs@FDA, BLA 125409). Supplement S-118, which added the adjuvant use in early HER2-positive breast cancer at high risk of recurrence, was approved on 12/20/2017 (Drugs@FDA, BLA 125409) (FDA approval letter of 12/20/2017). Supplement S-141, approved on 04/23/2026, added the additional APHINITY overall survival data to the label (FDA approval letter of 04/23/2026). The current label was revised in 04/2026 (Perjeta label of 04/2026).

EMA

At the EMA, Perjeta has had a marketing authorization since 03/04/2013 (Perjeta page at the EMA). The extension for adjuvant use was assessed in procedure II/0034, with an opinion from the committee for medicinal products for human use on 04/26/2018 (EMA assessment report, 2018). In that procedure, the indication was restricted to patients at high risk of recurrence, defined as node-positive or hormone receptor-negative (EMA assessment report, 2018). In the query of 10/24/2026, the summary of product details on the EMA page lists the metastatic and neoadjuvant indications, so it is worth checking the current text of the summary of product characteristics before citing the European adjuvant indication (Perjeta page at the EMA).

How NEXO helps train this reasoning

In NEXO, the case of the day is fictional, with a real clinical presentation and up to six progressive clues, and you propose the diagnosis by looking for the ICD-10 code. Adjuvant pertuzumab is a good exercise because the same decision changes with the number of lymph nodes. The post on case-based learning explains why this format fixes knowledge.

Three exercises with cases

Change the lymph nodes. Say what changes if all of the nurse's lymph nodes were negative and the hormone receptor were positive.

Change the heart. Say what you would do if the ejection fraction fell from 58 to 46 percent in the middle of treatment.

Change the order. Say what changes if she had had treatment before surgery and the specimen showed residual disease.

The post on simulation of a consultation helps train the conversation with the patient about absolute benefit and adverse effects.

The limits on use of the game are described on the NEXO economy page. If you research teaching of clinical reasoning, the page for researchers explains how to get in touch. Professionals who write or review cases find information on curation and on creators, and institutions can learn about the proposal on the for partnerships page.

Frequently asked questions

Does adjuvant pertuzumab cure breast cancer?

It reduces the risk of recurrence, especially with node-positive disease, but it does not guarantee a cure (von Minckwitz et al., 2017).

What is the dose?

840 mg for the first dose and then 420 mg every 3 weeks, for 1 year, up to 18 cycles (Perjeta label of 04/2026).

Is it worth it without node-positive disease?

In the study, no effect was detected in this group (von Minckwitz et al., 2017). The decision must weigh each patient's risk.

Does pertuzumab increase the risk to the heart?

Serious events were rare, and the long-term analysis showed no clear increase compared with placebo (de Azambuja et al., 2023).

What is the most common adverse effect?

Diarrhea, especially during chemotherapy (von Minckwitz et al., 2017).

Final checklist

• I counted the positive lymph nodes in the report.
• I checked the hormone receptor.
• I translated the hazard ratio into absolute benefit.
• I requested an ejection fraction before starting.
• I planned the antibodies after the anthracycline, with the taxane.
• I gave guidance on diarrhea and hydration.
• I gave guidance on contraception.
• I explained that the goal is to reduce the risk of recurrence.

Want to practice reasoning with progressive clues? Play the case of the day.

References

1. Bulbul A, Araujo-Mino E, Dayao ZR. The Conundrum of Adjuvant HER2 Treatment Options. Front Oncol. 2018. PMID 29900124.
2. Copeland AC, Anders CK. Dual HER2-Targeting in the Adjuvant Setting: Where We Have Been and Where We Are Going. Oncology (Williston Park). 2018. PMID 30334236.
3. Debiasi M, Polanczyk CA, Ziegelmann P, et al. Efficacy of Anti-HER2 Agents in Combination With Adjuvant or Neoadjuvant Chemotherapy for Early and Locally Advanced HER2-Positive Breast Cancer Patients: A Network Meta-Analysis. Front Oncol. 2018. PMID 29872641.
4. European Medicines Agency. CHMP extension of indication variation assessment report. Perjeta. Procedure No. EMEA/H/C/002547/II/0034. 26/04/2018. Official source.
5. European Medicines Agency. Perjeta | European Medicines Agency (EMA). Accessed on 24/10/2026. Official source.
6. Food and Drug Administration. BLA 125409/S-113 BLA 125409/S-118 SUPPLEMENT APPROVAL. Approval letter of 20/12/2017. Official source.
7. Food and Drug Administration. BLA 125409/S-141. SUPPLEMENT APPROVAL. Approval letter of 23/04/2026. Official source.
8. Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs. BLA 125409, Perjeta. Accessed on 24/10/2026. Official source.
9. Genentech. PERJETA® (pertuzumab) injection, for intravenous use. Package insert revised in 04/2026. Official source.
10. Ishii K, Morii N, Yamashiro H. Pertuzumab in the treatment of HER2-positive breast cancer: an evidence-based review of its safety, efficacy, and place in therapy. Core Evid. 2019. PMID 31802990.
11. Kirschbrown WP, Kågedal M, Wang B, et al. Pharmacokinetic and exploratory exposure-response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study. Cancer Chemother Pharmacol. 2019. PMID 30976844.
12. Krawczyk N, Fehm T, Ruckhaeberle E, et al. Post-Neoadjuvant Treatment in HER2-Positive Breast Cancer: Escalation and De-Escalation Strategies. Cancers (Basel). 2022. PMID 35740667.
13. Lambertini M, Fielding S, Loibl S, et al. Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted Therapy. J Natl Cancer Inst. 2022. PMID 35512402.
14. Mattar A, Cavalcante FP, Correa-Netto NF, et al. Impact of anti-HER2 therapies on potentially avoidable deaths from stage II and III HER2-positive breast cancer in the Brazilian public healthcare system. Breast. 2026. PMID 42826678.
15. Maurer C, Agostinetto E, Ameye L, et al. Association of statin use on survival outcomes of patients with early-stage HER2-positive breast cancer in the APHINITY trial. Breast Cancer Res Treat. 2025. PMID 40293644.
16. Stucci LS, Pisino M, D'Addario C, et al. Management of HER2-Positive Early Breast Cancer in Italy: A Maze Presenting Opportunities and Challenges. Front Oncol. 2022. PMID 35664788.
17. Valachis A, Liu X, Acs B, et al. A nationwide population-based study on the incidence and prognosis of HER2-positive breast cancer eligible for adjuvant pertuzumab in the modern era of neoadjuvant therapy. Breast. 2026. PMID 42288056.
18. de Azambuja E, Agostinetto E, Procter M, et al. Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial. ESMO Open. 2023. PMID 36681013.
19. von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med. 2017. PMID 28581356.